Ferreira-Divino, Luis F.
Suvitaival, Tommi
Rotbain Curovic, Viktor
Tofte, Nete
Trošt, Kajetan
Mattila, Ismo M.
Theilade, Simone
Winther, Signe A.
Hansen, Tine W.
Frimodt-Møller, Marie
Legido-Quigley, Cristina
Rossing, Peter
Article History
Received: 11 May 2022
Accepted: 5 July 2022
First Online: 18 July 2022
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki and approved by the local ethics committee in the Capital Region of Denmark. All participants gave written informed consent to the original study and the research biobank.
: Not applicable.
: P.R. reports having given lectures for AstraZeneca, Novo Nordisk, Eli Lilly, Bayer, Sanofi, and Boehringer Ingelheim; has served as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Astellas Gilead, and Novo Nordisk (all fees given to Steno Diabetes Center Copenhagen). S.T. has served as a consultant on advisory boards for Novo Nordisk. M.F.M reports having received research grants from Novo Nordisk and speaking fees from Boehringer Ingelheim, Novartis, Baxter and Sanofi. Since completion of data collection N.T. and S.A.W. are full-time employees of Novo Nordisk A/S.